Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
Head and Neck, Locally Advanced, Squamous Cell Carcinoma, SCCHN, Untreated, High Risk, Intermediate Risk, Radiation Therapy, Cisplatin
Brief summary
The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these combinations. Pembrolizumab is an immune therapy, a drug that stimulates the immune system to fight cancer, and is FDA approved in lung cancer and melanoma.
Detailed description
The study regimen consists of cisplatin and radiation for all patients, the standard treatment for head and neck cancer. All patients will also receive pembrolizumab (the study drug), and will be randomized to two treatment schedules: either pembrolizumab with cisplatin-radiation, or pembrolizumab after completing cisplatin-radiation.
Interventions
DRUGPembrolizumab
In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
DRUGCisplatin
Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
RADIATIONIMRT
IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
Sponsors
Merck Sharp & Dohme LLC
Dan Zandberg
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent * If a woman of childbearing potential, documentation of negative pregnancy * Histologically-confirmed head and neck squamous cell carcinoma with no evidence of distant metastasis. The primary site may be the oral cavity, oropharynx, larynx, or hypopharynx. Patients with squamous cell carcinoma of unknown primary, metastatic to cervical lymph nodes, are permitted to enroll. * High risk or intermediate risk disease, defined below. Staging evaluation should be determined by imaging studies and complete head and neck exam in accordance with the American Joint committee on Cancer Staging Manual, 7th edition. o High risk patient must meet one of the following criteria: * Surgically unresectable oral cavity. Patients who are technically resectable but refuse surgery due to morbidity (eg. total glossectomy) are also eligible. Medically inoperable patients are not eligible. * Larynx: T4 any N; T2-3 and ≥ N2a * Hypopharynx: T1-2N1-3 or T3-4N0-3 * Oropharynx: p16(-) AND T3-4 or ≥ N2a * Unknown primary: p16(-) AND ≥ N2a o Intermediate risk patients must meet one of the following criteria: * Oropharynx: p16(+) AND one of the following * T3 or ≥ N2a AND ≥ 10 pack-years tobacco exposure (see Tobacco Assessment Form, Appendix A) * T4 or N3 disease irrespective of tobacco exposure * Unknown primary: p16(+) AND one of the following * ≥ N2a AND ≥ 10 pack-years tobacco exposure * N3 disease irrespective of tobacco exposure * Patients must be untreated with curative-intent surgery for current diagnosis of Stage III, IVa, or IVb disease. Diagnostic biopsy of primary tumor and/or nodal sites is permitted. * Diagnostic simple tonsillectomy is permitted, provided patient has RECIST-measurable nodal disease. * Patients with a second HNSCC primary tumor are eligible for this study, provided more than 2 years have elapsed since the first diagnosis of HNSCC, the original tumor was managed with surgery only (no adjuvant chemotherapy or radiotherapy), and has not recurred. * Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 differentiated thyroid carcinoma (resected or management deferred), who are eligible. * No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation treatment for head and neck cancer. * Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least 2 years have elapsed. * Patients must be untreated with radiation above the clavicles. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 * Age ≥ 18 * Patients must have measurable disease according to RECIST 1.1 * Patients must demonstrate adequate organ function as defined. * Sexually active patients must agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug.
Exclusion criteria
* Nasopharyngeal primary site * Current participation in or previous participation in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment. * History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent. * Distant metastatic disease including CNS or leptomeningeal metastases is not allowed. * History of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. * Received prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. * History of second malignancy within 2 years prior to Study Day 1 (except for excised and cured non-melanoma skin cancer, carcinoma in situ of breast or cervix, superficial bladder cancer, or T1a or T1b prostate cancer comprising \< 5% of resected tissue with normal prostate specific antigen (PSA) since resection). * Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. * Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). * Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). * Received a live vaccine within 30 days prior to the first dose of trial treatment. * Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * Significant pulmonary disease, including pulmonary hypertension, interstitial lung disease, or active, non-infectious pneumonitis. * History or current evidence of any other medical or psychiatric condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Peripheral neuropathy ≥ Grade 2 * Significant cardiovascular disease, including: * Cardiac failure New York Heart Association (NYHA) class III or IV. * Myocardial infarction, severe or unstable angina within 6 months prior to Study Day 1. * History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular fibrillation). * Ventricular cardiac arrhythmias requiring anti-arrhythmic medications. * Known left ventricular ejection fraction (LVEF) ≤ 50%. * Significant thrombotic or embolic events within 3 months prior to Study Day 1. * Major surgery within 6 weeks prior to Study Day 1 (subjects must have completely recovered from any previous surgery prior to Study Day 1). Biopsy, diagnostic tonsillectomy, airway tumor debulking or excisional lymph node biopsy do not constitute major surgery. * Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug. * Significant electrolyte imbalance prior to enrollment (note that patients may be supplemented to achieve acceptable electrolyte values): * Hypomagnesemia \<1.2 mg/dL or 0.5 mmol/L. * Hypokalemia \< 3.0 mmol/L. * Women must not be pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year Locoregional Failure Rate | Up to 3 years | Percent probability of participants for which time to locoregional failure (TTLRF) (calculated from treatment initiation to locoregional failure, or censored at other failure, death, or the last follow up; death is not an event) is less than 3 years. Locoregional failure is disease recurrence in either the location or regional location of the original disease, as opposed to a distant site. |
| Progression-free Survival at ≤12 Months | Up to 12 months | Probability of participants (expressed as a percentage) without disease progression at less than or equal to12 after start of treatment: Complete Response (CR) + Partial Response (PR)/total number of patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). |
| Progression-free Survival at ≤ 36 Months | Up to 36 months | Probability of participants (expressed as a percentage) without disease progression at less than or equal to 36 months after start of treatment: Complete Response (CR) + Partial Response (PR)/total number of patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). |
| Progression-free Survival at ≤ 48 Months | Up to 48 months | Probability of participants (expressed as a percentage) without disease progression time from treatment initiation to disease progression or death from any cause or last follow up. Per RECIST v1.1: Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). |
| Acute Toxicity / DLT Rate | Up to 6 months | The number of patients who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0 |
| 1-year Locoregional Failure Rate | Up to 1 year | Percent probability of participants for which time to locoregional failure (TTLRF) (calculated from treatment initiation to locoregional failure, or censored at other failure, death, or the last follow up; death is not an event) is less than 1 year. Locoregional failure is disease recurrence in either the location or regional location of the original disease, as opposed to a distant site. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 48 months | The length of time from start of study treatment that patients are still alive. |
| Overall Survival (OS) at ≤ 12 Months | Up to12 months | Probability of patients (expressed as a percentage) still alive at less than or equal to 12 months after start of study. |
| Overall Survival (OS) at ≤ 36 Months | Up to 36 months | Probability of patients (expressed as a percentage) still alive at less than or equal to 36 months after start of study. |
| Overall Survival (OS) at ≤ 48 Months | Up to 48 months | Probability of patients (expressed as a percentage) still alive at less than or equal to 48 months after start of study. |
| Progression-free Survival (PFS) | Up to 48 months | Median number of months from treatment initiation to disease progression or death from any cause or last follow up. Per RECIST v1.1 Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisplatin and radiation and given every 3 weeks
Pembrolizumab: In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
Cisplatin: Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
IMRT: IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan. | 41 |
| Cisplatin + Radiation + Pembrolizumab - Sequential Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplatin and radiation.
Pembrolizumab: In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
Cisplatin: Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
IMRT: IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan. | 39 |
| Total | 80 |
Baseline characteristics
| Characteristic | Cisplatin + Radiation + Pembrolizumab - Sequential | Total | Cisplatin + Radiation + Pembrolizumab - Concurrent |
|---|---|---|---|
| Age, Continuous | 63.64 years STANDARD_DEVIATION 6.85 | 63.7184 years STANDARD_DEVIATION 7.1725 | 63.79 years STANDARD_DEVIATION 7.55 |
| ECOG ECOG = 0 | 31 Participants | 67 Participants | 36 Participants |
| ECOG ECOG = 1 | 8 Participants | 12 Participants | 4 Participants |
| ECOG ECOG = 2 | 0 Participants | 1 Participants | 1 Participants |
| Histology Not applicable | 0 Participants | 1 Participants | 1 Participants |
| Histology SQUAMOUS CELL CA KERATINIZING, NOS | 0 Participants | 1 Participants | 1 Participants |
| Histology SQUAMOUS CELL CA METASTATIC, NOS | 2 Participants | 4 Participants | 2 Participants |
| Histology SQUAMOUS CELL CARCINOMA, NOS | 37 Participants | 74 Participants | 37 Participants |
| N Stage N Stage = 0 | 2 Participants | 5 Participants | 3 Participants |
| N Stage N Stage = 1 | 5 Participants | 6 Participants | 1 Participants |
| N Stage N Stage = 2 | 29 Participants | 57 Participants | 28 Participants |
| N Stage N Stage = 3 | 2 Participants | 8 Participants | 6 Participants |
| N Stage N Stage = Not Available | 1 Participants | 4 Participants | 3 Participants |
| p16 for oropharynx Negative for p16 for oropharynx | 17 Participants | 33 Participants | 16 Participants |
| p16 for oropharynx Not Available | 1 Participants | 4 Participants | 3 Participants |
| p16 for oropharynx Positive for p16 for oropharynx | 21 Participants | 43 Participants | 22 Participants |
| Primary Site Hypopharynx | 1 Participants | 5 Participants | 4 Participants |
| Primary Site Larynx | 8 Participants | 18 Participants | 10 Participants |
| Primary Site Oropharynx | 30 Participants | 57 Participants | 27 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 5 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 35 Participants | 74 Participants | 39 Participants |
| Sex: Female, Male Female | 1 Participants | 5 Participants | 4 Participants |
| Sex: Female, Male Male | 38 Participants | 75 Participants | 37 Participants |
| Stage Not Stage 3 or 4 | 6 Participants | 10 Participants | 4 Participants |
| Stage Stage = 3 | 1 Participants | 4 Participants | 3 Participants |
| Stage Stage = 4 | 32 Participants | 66 Participants | 34 Participants |
| T Stage T Stage = 1 | 1 Participants | 2 Participants | 1 Participants |
| T Stage T Stage = 2 | 7 Participants | 18 Participants | 11 Participants |
| T Stage T Stage = 3 | 10 Participants | 20 Participants | 10 Participants |
| T Stage T Stage = 4 | 20 Participants | 36 Participants | 16 Participants |
| T Stage T Stage = Not Available | 1 Participants | 4 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 11 / 41 | 6 / 39 |
| other Total, other adverse events | 38 / 41 | 38 / 39 |
| serious Total, serious adverse events | 21 / 41 | 10 / 39 |
Outcome results
Primary
1-year Locoregional Failure Rate
Percent probability of participants for which time to locoregional failure (TTLRF) (calculated from treatment initiation to locoregional failure, or censored at other failure, death, or the last follow up; death is not an event) is less than 1 year. Locoregional failure is disease recurrence in either the location or regional location of the original disease, as opposed to a distant site.
Time frame: Up to 1 year
Population: All treated patients.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | 1-year Locoregional Failure Rate | 15 percent probability of participants |
| Cisplatin + Radiation + Pembrolizumab - Sequential | 1-year Locoregional Failure Rate | 4 percent probability of participants |
Primary
3-year Locoregional Failure Rate
Percent probability of participants for which time to locoregional failure (TTLRF) (calculated from treatment initiation to locoregional failure, or censored at other failure, death, or the last follow up; death is not an event) is less than 3 years. Locoregional failure is disease recurrence in either the location or regional location of the original disease, as opposed to a distant site.
Time frame: Up to 3 years
Population: All treated patients.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | 3-year Locoregional Failure Rate | 26 percent probability of participants |
| Cisplatin + Radiation + Pembrolizumab - Sequential | 3-year Locoregional Failure Rate | 4 percent probability of participants |
Primary
Acute Toxicity / DLT Rate
The number of patients who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0
Time frame: Up to 6 months
Population: All treated patients.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Acute Toxicity / DLT Rate | 3 Participants |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Acute Toxicity / DLT Rate | 0 Participants |
Primary
Progression-free Survival at ≤12 Months
Probability of participants (expressed as a percentage) without disease progression at less than or equal to12 after start of treatment: Complete Response (CR) + Partial Response (PR)/total number of patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Up to 12 months
Population: All patients that received treatment and were radiologically evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Progression-free Survival at ≤12 Months | 71 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Progression-free Survival at ≤12 Months | 83 percentage of patients |
Primary
Progression-free Survival at ≤ 36 Months
Probability of participants (expressed as a percentage) without disease progression at less than or equal to 36 months after start of treatment: Complete Response (CR) + Partial Response (PR)/total number of patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Up to 36 months
Population: All patients that received treatment and were radiologically evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Progression-free Survival at ≤ 36 Months | 57 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Progression-free Survival at ≤ 36 Months | 75 percentage of patients |
Primary
Progression-free Survival at ≤ 48 Months
Probability of participants (expressed as a percentage) without disease progression time from treatment initiation to disease progression or death from any cause or last follow up. Per RECIST v1.1: Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Up to 48 months
Population: All patients that received treatment and were radiologically evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Progression-free Survival at ≤ 48 Months | 49 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Progression-free Survival at ≤ 48 Months | 67 percentage of patients |
Secondary
Overall Survival (OS)
The length of time from start of study treatment that patients are still alive.
Time frame: Up to 48 months
Population: All patients on study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Overall Survival (OS) | NA months |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Overall Survival (OS) | NA months |
Secondary
Overall Survival (OS) at ≤ 12 Months
Probability of patients (expressed as a percentage) still alive at less than or equal to 12 months after start of study.
Time frame: Up to12 months
Population: All patients on study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Overall Survival (OS) at ≤ 12 Months | 82 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Overall Survival (OS) at ≤ 12 Months | 95 percentage of patients |
Secondary
Overall Survival (OS) at ≤ 36 Months
Probability of patients (expressed as a percentage) still alive at less than or equal to 36 months after start of study.
Time frame: Up to 36 months
Population: All patients on study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Overall Survival (OS) at ≤ 36 Months | 71 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Overall Survival (OS) at ≤ 36 Months | 88 percentage of patients |
Secondary
Overall Survival (OS) at ≤ 48 Months
Probability of patients (expressed as a percentage) still alive at less than or equal to 48 months after start of study.
Time frame: Up to 48 months
Population: All patients on study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Overall Survival (OS) at ≤ 48 Months | 71 percentage of patients |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Overall Survival (OS) at ≤ 48 Months | 83 percentage of patients |
Secondary
Progression-free Survival (PFS)
Median number of months from treatment initiation to disease progression or death from any cause or last follow up. Per RECIST v1.1 Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Up to 48 months
Population: All patients that received treatment and were radiologically evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cisplatin + Radiation + Pembrolizumab - Concurrent | Progression-free Survival (PFS) | 37.00 months |
| Cisplatin + Radiation + Pembrolizumab - Sequential | Progression-free Survival (PFS) | NA months |